You are here

Funding Opportunities

Updated September 24, 2018

Tri-council:

CIHR Catalyst Grant - Cannabis Research in Urgent Priority Areas
  • The purpose of this current funding opportunity is to strengthen the evidence base and expand cannabis research in these identified areas, to build research capacity and/or to inform the development of future larger scale research projects.
  • Supports cannabis and pain management: Research into the potential therapeutic use of cannabis (recreational or prescribed) for pain management.
  • $125,000 for up to 1 year
  • Registration deadline: September 18, 2018
  • Application Deadline: October 10, 2018
CIHR Catalyst Grant : Post-Traumatic Stress Injuries (PTSI) among Public Safety Personnel (PSP)
  • This Funding Opportunity is expected to: Strengthen and expand the evidence base needed to inform current and future policies, practices and programs related to PTSI in PSP; and Improve the mental wellness and resilience of Canada’s PSP through innovative research.
  • $150,000 for up to 1 year
  • Application Deadline: September 25, 2018
CIHR Operating Grant: Transitions in Care - Best and Wise Practices Grants
  • Develop relevant research capacity leading up to future TiC funding opportunities;
  • Inform actionable health system changes within the TiC Focus Areas by supporting systematic identification and collating of transitions in care knowledge gaps and/or identification of effective evidence-based interventions and/or policies;
  • Facilitate the identification of relevant transitions in care stakeholders and partnerships, with a particular focus on partnerships that can support community-based research and approaches that have potential for equitable spread and scale between communities, at a regional and/or national level.
  • $100,000 for up to one (1) year
  • Application deadline: October 10, 2018
SSHRC 2018 Insight Grant competition
  • Insight Grants support long-term research initiatives in the social sciences and humanities. Funding is available to emerging and established scholars for projects conducted by an individual researcher or team of researchers.
  • $7,000 to $400,000 over 2 to 5 years (max $100,000/year.)
  • Application deadline: October 15, 2018
CIHR Prize : The CIHR Institute of Human Development, Child and Youth Health (IHDCYH)
  • A unique opportunity to submit short videos (recommended maximum length of 5 minutes) sharing evidence-based messages in the area of maternal, reproductive, child and youth health. This competition encourages the production of videos that present a clear evidence-based message to a lay audience that is designed to have a positive impact on the health of children, youth and families.
  • $3,000 to the first place prize; $1,000 to the runner-up prize; $750 each to two specially commended prizes.
  • Submission due October 16, 2018
SSHRC Connection Grant
  • Supports workshops, colloquiums, conferences, forums, summer institutes or other events or outreach activities geared toward short-term, targeted knowledge mobilization initiatives. These events and activities represent opportunities to exchange knowledge and to mobilize research with those participating.
  • $7,000 to $50,000 over one year, with higher amounts considered on an exceptional basis.
  • Application Deadlines (4 cycles/year): November 1, 2018
Government of Canada: Going Global Innovation (GGI) 
  • The GGI program is specifically designed to promote and enhance Canada’s international innovation efforts. The program supports researchers who aim to commercialize technology by pursuing collaborative international research and development (R&D) opportunities through partnerships with key players in foreign markets. Eligible beneficiaries are Canadian innovators from small or medium size enterprises, universities and nongovernment research centres.
  • GGI provides assistance by contributing up to 75% of eligible expenses, up to a maximum of $75,000 for any approved project. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.
  • Application Deadline: Continuous.

Other Canadian Funding competitions:

UBC VP Research and Innovation: Grants for Catalyzing Research Clusters
  • Targeted at catalyzing research initiatives at UBC. Funding is to be used strategically by recipients to attract further opportunities for cluster development
  • $100,000 to 200,000 for 1 year
  • NOI due Sep 17 full application due Nov 12, 2018
Broad Medical Research Program at CCFA (BMRP-CCFA): Inflammatory Bowel Disease Grants
  • For innovative proposals (clinical or basic) that will lead to improvements in the prevention, diagnosis or therapy of Crohn’s disease or ulcerative colitis. Preference is given to proposals for work conducted with human samples or patients. Research using non-human material should lead to translational benefits to patients with IBD.
  • There is no fixed upper or lower limit of funding, but applicants should keep in mind that BMRP-CCFA has limited funds. Funding can be requested for up to two years, but grants generally are funded only one year at a time.
  • LoI is accepted all year round.

    International Funding competitions:

    USA NIH:

    NIH Heal Initiative
    • As part of the HEAL (Helping to End Addiction Long-term) Initiative, NIH will support research on how chronic pain develops and on new treatments to alleviate chronic pain.  HEAL will develop a data sharing collaborative, new biomarkers for pain, and a clinical trials network for testing new pain therapies
    • Notices of Intent to Publish FOAs for a Clinical Trials Network on Pain Research
    NIH Research Program to Explore the Transition From Acute to Chronic Pain
    • Acute to Chronic Pain Signatures (A2CPS) program to investigate the biological characteristics underlying the transition from acute to chronic pain.
    • Funding Opportunity Announcements for researchers to apply to participate in the A2CPS program are now available.
    • For more information, please contact Rachel Britt, PhD, 301-435-0968, Rachel.britt@nih.gov.
    • Letter of Intent (LOI) Due Date: Sep 24, 2018
    • Application Due Date: October 24, 2018
    PAR-14-182: Exploratory Clinical Trials of Mind and Body Interventions for NCCAM High Priority Research Topics (R34)
    • Supports early phase clinical trials of mind and body approaches for conditions that have been identified by NCCAM as high priority research topics.
    • Cycle III due date: September 25, 2018
    PAS-18-624: Mechanistic Investigations of Psychosocial Stress Effects on Opioid Use Patterns (R01: Clinical Trial Optional)
    • Seeks to address two specific mechanistic pathways via which psychosocial stress may modulate opioid use trajectories.
      • The first pathway is through its effects on cognitive and affective systems that are also altered in OUDs.
      • Second related pathway is substantial co-morbidity between OUD and stress-related affective disorders, including depression, anxiety and PTSD.
    • Cycle III due date: September 25, 2018
    PA-18-376, PA-14-474, PA-14-384: Self-Management for Health in Chronic Conditions (R01, R15, R21)
    • Cycle III due date: September 25, 2018
    PPA-15-141, PA-15-142, PA-15-143: International Research Collaborations on Drug Abuse and Addiction Research (R03, R01, R21)
    • Cycle III due date: September 25, 2018
    PAR-14-225: Neurobiology of Migraine (R01)
    • Supports innovative research that will elucidate the mechanisms underlying migraine; expand our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression; and explore new therapeutic targets and therapies for acute migraine management and longer-term prevention.
    • Cycle III due date: September 25, 2018
    PA-16-311, PA-16-313, PA-16-312: Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R01, R03, R21)
    • Promotes preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations
    • Develops effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments
    • Budgets are not limited but need to reflect the actual needs of the proposed project
    • Maximum of 5 years
    • Cycle III due date: September 25, 2018
    PA-14-244: Research on Chronic Overlapping Pain Conditions (R01)
    • encourages epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain.
    • Cycle III due date: October 5, 2018
    PAS-18-625: Mechanistic Investigations of Psychosocial Stress Effects on Opioid Use Patterns (R21: Clinical Trial Optional)
    • Invites innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD).
    • Encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate.
    • Cycle III: due date October 16, 2018
    RFA-NS-18-041: Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)
    • Purpose is to promote the discovery of strong candidate biomarkers and endpoints for pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.  Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical validation of pain biomarkers, biomarker signatures, and/or endpoints. Although research supported by this FOA can include animal studies, it must also include preliminary human validation using carefully standardized human samples or human clinical studies. The goal of this initiative is to deliver candidate biomarkers, biomarker signatures, and/or endpoints that are ready for advanced clinical and analytical validation research.
    • Letter of Intent due October 27, 2018
    • Application due date: Cycle I Nov 27, 2018
    • Cycle II March 7, 2019
    • Cycle III November 25, 2019
    PAR-18-742: Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)
    • Enourages research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response.
    • Application due date: Nov 13, 2018

    Other USA Opportunities:

    American Foundation for Suicide Prevention
    • Priority area research applications are reviewed along with the general pool of grant applications, with priority given to strong grants in the designated areas: Opioids and Suicide; and Pain and Suicide. Distinguished Investigator Innovation Grants and Young Investigator Innovation Grants are also available.
    • $100,000 USD over 2 years.
    • Application due November 15, 2018
    2019 Rita Allen Foundation Award in Pain
    • The Rita Allen Foundation (RAF) and American Pain Society (APS) announce the 2019 Award in Pain. The RAF and APS may award two grants in the amount of $50,000 annually, for a period of up to three years to those research proposals demonstrating the greatest merit and potential for success.
    • Application due date: Dec 17, 2018
    New Funding Opportunity for Pain Research Through OnPAR:
    • OnPAR provides innovative and exceptional research applications with a second opportunity for funding
    • OnPAR seeks to provide a funding alternative to the research community’s restraints imposed by limitations in government funding. OnPAR members include private foundations, pharmaceuticals and other private funders that will review research ideas submitted for consideration
    • OnPAR accepts abstracts from CIHR
    • OnPar has now expanded to include pain research projects.

    Founding Partners